Lumena Pharmaceuticals

At its core, Mirum Pharma is a business development success story. CEO Chris Peetz sat down with In Vivo to discuss Mirum’s commercial momentum, near-term catalysts and the company’s vision for beco

Since acquiring a pair of mid-stage apical sodium-dependent bile acid transporter (ASBT) inhibitors from Shire PLC in 2018, Mirum Pharmaceuticals has been working to build a case for both in pedia

Fourteen of the 28 biopharmaceutical companies that launched initial public offerings in the US during the first half of 2019 are providing IPO investors with a negative return and one is trading flat

Reneo Pharmaceuticals Inc. has been developing REN001 for rare genetic mitochondrial diseases for more than a year. But now that it has two clinical trials under way and a third planned to start late